Latest news with #COR
News18
2 days ago
- Politics
- News18
Tree plantation drive inaugurated in Latur
Agency: PTI Last Updated: Latur, Aug 17 (PTI) The administration in Maharashtra's Latur district launched the second edition of its plantation drive on Sunday, roping in government bodies and NGOs in its efforts. Collector Varsha Thakur-Ghuge inaugurated the Latur Harotstosav at Ganjgolai, and students, government employees and citizens took out a rally from Mahatma Gandhi Chowk to Ganjgolai to mark the occasion. The district administration has been making efforts to accelerate tree plantation with the involvement of government bodies, NGOs, and citizens. Speaking on the occasion, the collector said, 'Latur has very few trees. To make the district greener, every citizen must join this campaign and turn it into a people's movement. The COVID-19 crisis has already taught us the value of oxygen. Villages, towns, and neighbourhoods must set up oxygen parks, while citizens should plant trees on farm bunds, roadsides, terraces, and open spaces." PTI COR ARU First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Yahoo
3 days ago
- Business
- Yahoo
Why Cencora (COR) is a Top Value Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Why Investors Should Pay Attention to This Value Stock Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. Cencora (COR) Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes. COR sits at a Zacks Rank #3 (Hold), holds a Value Style Score of A, and has a VGM Score of A. Compared to the Medical Services industry's P/E of 16.7X, shares of Cencora are trading at a forward P/E of 18.6X. COR also has a PEG Ratio of 1.4, a Price/Cash Flow ratio of 14.8X, and a Price/Sales ratio of 0.2X. Many value investors pay close attention to a company's earnings as well. For COR, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.13 to $15.88 per share for 2025. COR boasts an average earnings surprise of 6.2%. COR should be on investors' short list because of its impressive earnings and valuation fundamentals, a good Zacks Rank, and strong Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Cencora Stock: Analyst Estimates & Ratings
Valued at a market cap of $56 billion, Cencora, Inc. (COR) sources and distributes pharmaceutical products for people and animals. The Conshohocken, Pennsylvania-based company provides essential support, encompassing clinical trial logistics and consulting to packaging, data analytics, and patient adherence programs. This healthcare company has outpaced the broader market over the past 52 weeks. Shares of COR have surged 21.6% over this time frame, while the broader S&P 500 Index ($SPX) has gained 20.6%. Moreover, on a YTD basis, the stock is up 28.7%, compared to SPX's 9.6% return. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Zooming in further, COR's outperformance looks even more pronounced when compared to the VanEck Pharmaceutical ETF's (PPH) 11% loss over the past 52 weeks and 3.2% YTD drop. On Aug. 6, Cencora released its Q3 results. Due to growth in both its U.S. and International healthcare solutions segments, the company's overall revenue improved 8.7% year-over-year to $80.7 billion, surpassing consensus estimates by a slight margin. Moreover, its adjusted EPS of $4 advanced 19.8% from the prior-year quarter and came in 5.8% above analyst expectations. Additionally, COR raised its fiscal 2025 adjusted EPS guidance, and now expects it to be between $15.85 and $16. Yet, its shares tumbled 2.9% after the earnings release. For the current fiscal year, ending in September, analysts expect COR's EPS to grow 15.9% year over year to $15.95. The company's earnings surprise history is promising. It surpassed the consensus estimates in each of the last four quarters. Among the 14 analysts covering the stock, the consensus rating is a "Strong Buy' which is based on 11 'Strong Buy,' and three 'Hold' ratings. This configuration is slightly more bullish than three months ago, with 10 analysts suggesting a 'Strong Buy' rating. On Aug. 11, JPMorgan Chase & Co. (JPM) analyst Richard Choe maintained a "Buy" rating on COR and set a price target of $344, implying a 19% potential upside from the current levels. The mean price target of $335 represents a 15.9% premium from COR's current price levels, while the Street-high price target of $355 suggests an ambitious upside potential of 22.8%. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
06-08-2025
- Business
- Globe and Mail
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
Cencora, Inc. COR reported third-quarter fiscal 2025adjusted earnings per share (EPS) of $4.00, which beat the Zacks Consensus Estimate of $3.78 by 5.8%. The bottom line also improved 19.8% year over year. GAAP EPS was $3.52, up 45.5% from the year-ago period's level. The significant gain was primarily driven by robust top-line growth. Revenue Details Revenues totaled $80.7 billion, up 8.7% year over year. The top line beat the Zacks Consensus Estimate by 0.5%. Segmental Analysis U.S. Healthcare Solutions Revenues in this segment totaled $72.9 billion, up 8.5% on a year-over-year basis. This improvement was driven by overall market growth on increased unit volume, including improved sales of GLP-1 drugs and specialty products. Segmental operating income totaled $901.8 million, up 29.1% year over year. Higher gross profit (as a result of increased product sales and the January 2025 acquisition of RCA) contributed to the upside, partly offset by increased operating expenses. International Healthcare Solutions This segment includes Alliance Healthcare, World Courier, Innomar and Profarma Specialty. Revenues amounted to $7.8 billion, up 10.5% year over year. The top line increased 8.8% at constant currency (cc). Operating income totaled $156.2 million, down 12.9% on a reported basis and 16.2% at cc. The reported decline was due to lower operating income at COR's global specialty logistics and specialized consulting services businesses. Margin Analysis Cencora reported an adjusted gross profit of $2.9 billion, up 20.7% on a year-over-year basis. As a percentage of revenues, the adjusted gross margin was 3.55%, up 36 basis points (bps) year over year. The company recorded an adjusted operating income of $1.1 billion, up 20.6% year over year. As a percentage of revenues, the adjusted operating margin was 1.31%, which expanded 13 bps from the year-ago quarter's level. Financial Update COR exited the fiscal third quarter with cash and cash equivalents worth $2.23 billion compared with $1.98 billion in the previous quarter. Cumulative net cash provided by operating activities totaled $741.7 million compared with $2.48 billion a year ago. Dividend Update Cencora's board of directors declared a quarterly dividend of 55 cents per share. The new dividend is payable on Sept. 2, 2025, to shareholders of record at the close of business on Aug. 15, 2025. FY25 Guidance The company updated its previous outlook for fiscal 2025 earnings and revenues, suggesting stronger earnings growth in the U.S. Healthcare Solutions segment. Adjusted EPS is now estimated to be in the $15.85-$16.00 range, up from the previous guidance of $15.70-$15.95. The Zacks Consensus Estimate for the same is pegged at $15.81. Total revenues are now projected to rise approximately 9% from the previous guidance of 8-10%. Sales at the U.S. Healthcare Solutions segment are now anticipated to grow in the range of 9-10% (previously 9-11%). For the International Healthcare solutions business, revenues are now projected to rise 6-7% from the previous guidance of 3-4%. On a cc basis, the International Healthcare Solutions segment's revenue growth is expected to be in the range of 7-8%, down from the previous guidance of 6-8%. Adjusted operating income is expected to improve 15-16% for fiscal 2025, up from the earlier guidance of 13.5-15.5%. Operating income for the U.S. Healthcare Solutions segment is now expected to improve 20-21% (previously 17.5-19.5%), while the same for the International Healthcare Solutions business is estimated to decline approximately 6% (previous decline of 1-4%) year over year and 5% at cc. Our Take Cencora exited the fiscal third quarter on a strong note, wherein its earnings and revenues beat the Zacks Consensus Estimate. The company's EPS guidance for fiscal 2025 was also above estimates. However, shares were down 0.8% in pre-market trading. So far this year, COR's shares have gained 29.4% against the industry 's decline of 3%. The S&P 500 Index was down 5% in the same time period. The company continues to witness robust segmental performance due to growth in all markets and strong demand for specialty products and GLP-1 drugs. Per management, Cencora delivered a solid performance by playing a crucial role in the healthcare system while maintaining efficiency throughout its business. The company has been focused on its priorities. It has thoughtfully deployed capital to deliver long-term growth. The acquisition of RCS appears promising, as it is expected to become accretive to this fiscal year's bottom line. However, COR's gross margin continues to be negatively impacted by lower-margin GLP-1 drugs and the lack of exclusive COVID-19 therapy sales, which had higher margins. The company's rising expenses to support business activities amid inflationary challenges put pressure on the operating margin. Cut-throat competition in the MedTech space is another headwind. COR's Zacks Rank & Other Key Picks COR carries a Zacks Rank #2 (Buy) at present. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. MEDP, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. Medpace Holdings, sporting a Zacks Rank #1 (Strong Buy) at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%. You can see the complete list of today's Zacks #1 Rank stocks here. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report
Washington Post
06-08-2025
- Business
- Washington Post
Cencora: Fiscal Q3 Earnings Snapshot
CONSHOHOCKEN, Pa. — CONSHOHOCKEN, Pa. — Cencora, Inc. (COR) on Wednesday reported fiscal third-quarter earnings of $687.4 million. On a per-share basis, the Conshohocken, Pennsylvania-based company said it had profit of $3.52. Earnings, adjusted for one-time gains and costs, came to $4 per share. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $3.78 per share.
